Citations

Showing 10 of 108083 citations.

The use of mini-invasive surgical techniques to treat refractory exit-site and tunnel infections in peritoneal dialysis patients: a clinical approach
Scalamogna, Antonio, Nardelli, Luca , Castellano, Giuseppe

Mayo Clinic

Journal of Nephrology | December 15, 2022 | Volume: 36 | Issue: 7 | Pages: 1743-1749

10.1007/s40620-022-01479-7 | PMID 36520366 Get It

Abstract Peritoneal dialysis—(PD) related infections continue to be a major cause of morbidity and mortality in patients on PD. Although great advances have been made in the prevention and treatment of infectious complications over the past two decades, catheter-related infections represent a significant cause of technical failure in PD. Recent studies support the role of exit-site/tunnel infections in causing peritonitis. Peritonitis secondary to tunnel infection led to catheter loss in most cases. Thus, removing the catheter when exit-site/tunnel infection is refractory to medical therapy has been recommended. This approach requires interrupting PD and, after the placement of a central venous catheter, and transferring the patient to haemodialysis. In order to continue PD, simultaneous catheter removal and replacement of the PD catheter has been suggested. Although simultaneous catheter removal and replacement avoids temporary haemodialysis, it implies the removal/reinsertion of the catheter and the immediate initiation of PD with the risk of mechanical complications, such as leakage and malfunction. Hence, several mini-invasive surgical techniques, such as curettage, cuff-shaving, removal of the superficial cuff, and partial reimplantation of the catheter, have been proposed as rescue treatments. These procedures may allow the rescue of the catheter with a success rate of 70–100%. Therefore, in case of refractory exit-site/tunnel infection, a mini-invasive surgical revision should be considered before removing the catheter.
Current Considerations in Surgical Treatment for Adolescents and Young Women with Breast Cancer
Murphy, Brittany L. , Pereslucha, Alicia M, Boughey, Judy C.

Mayo Clinic

Healthcare | December 15, 2022 | Volume: 10 | Issue: 12 | Pages: 2542

10.3390/healthcare10122542 | PMID 36554065 Get It

Adolescents and young women (AYA) with breast cancer represent a unique patient population, compared to the general population with breast cancer. We performed a literature review to evaluate the factors that influenced the surgical outcomes in this patient population. Fifty-two studies were identified, which evaluated breast surgery type, axillary surgery, contralateral prophylactic mastectomy (CPM), surgical timing, psychological factors, disparities, and imaging use. AYA patients had equivalent oncologic outcomes with breast conserving surgery (BCS) or mastectomy. CPM did not improve survival. There are limited data on axillary management in the AYA population, and while more data would be beneficial, this is currently extrapolated from the general breast cancer population. A shorter time to initiate treatment correlated to better outcomes, and disparities need to be overcome for optimal outcomes. AYA patients appreciated involvement in clinical decisions, and shared decision making should be considered whenever possible. Providers must keep these factors in mind when counseling AYA patients, regarding the surgical management of breast cancer.
Symptomatic Hyperammonemia Secondary to Recombinant Erwinia Asparaginase
Martin, Catherine E. , Kohorst, Mira A. , Kalmes, Jessica L., Galardy, Paul J. , Khan, Shakila P. , Kuhn, Alexis , DeFino, Catherine E. , Kuhn, Alexis K , Ferdjallah, Asmaa , Kalmes, Jessica, Johnson, Heather M.

Mayo Clinic

No container title available | December 15, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.167108956.65037910/v1 Get It

PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemia
Li, Yizhen , Li, Zhenhua , Paietta, Elisabeth , Litzow, Mark R. , Konopleva, Marina , Yu, Jiyang , Inaba, Hiroto , Yu, Jiyang , Inaba, Hiroto , Ribeiro, Raul C , Pui, Ching-Hon , Yang, Jun J.J. , Moriyama, Takaya , Yoshimura, Satoshi , Zhao, Xujie , Yang, Xu

Mayo Clinic

Science Advances | December 14, 2022 | Volume: 8 | Issue: 50 | Pages: No page available

10.1126/sciadv.add6403 | PMID 36516256 Get It

Blinatumomab is an efficacious immunotherapeutic agent in B cell acute lymphoblastic leukemia (B-ALL). However, the pharmacogenomic basis of leukemia response to blinatumomab is unclear. Using genome-wide CRISPR, we comprehensively identified leukemia intrinsic factors of blinatumomab sensitivity, i.e., the loss of CD58 as a top driver for resistance, in addition to CD19 . Screening 1639 transcription factor genes, we then identified PAX5 as the key activator of CD58. ALL with the PAX5 P80R mutation also expressed the lowest level of CD58 among 20 ALL molecular subtypes in 1988 patients. Genome editing confirmed the effects of this mutation on CD58 expression and blinatumomab sensitivity in B-ALL, with validation in patient leukemic blasts. We described a PAX5-driven enhancer at the CD58 locus, which was disrupted by PAX5 P80R, and the loss of CD58 abolished blinatumomab-induced T cell activation with global changes in transcriptomic/epigenomic program. In conclusion, we identified previously unidentified genetic mechanisms of blinatumomab resistance in B-ALL, suggesting strategies for genomics-guided treatment individualization.
Arf GTPase activates the WAVE regulatory complex through a distinct binding site
Yang, Sheng , Tang, Yubo , Liu, Yijun , Brown, Abbigale J., Schaks, Matthias , Ding, Bojian , Kramer, Daniel A. , Miętkowska, Magdalena, Alekhina, Olga , Billadeau, Daniel D. , Wang, Junmei , Chen, Baoyu , Alekhina, Olga , Billadeau, Daniel D , Chowdhury, Saikat , Wang, Junmei , Rottner, Klemens , Chen, Baoyu , Li, Ding

Mayo Clinic

Science Advances | December 14, 2022 | Volume: 8 | Issue: 50 | Pages: No page available

10.1126/sciadv.add1412 | PMID 36516255 Get It

Cross-talk between Rho- and Arf-family guanosine triphosphatases (GTPases) plays an important role in linking the actin cytoskeleton to membrane protrusions, organelle morphology, and vesicle trafficking. The central actin regulator, WAVE regulatory complex (WRC), integrates Rac1 (a Rho-family GTPase) and Arf signaling to promote Arp2/3-mediated actin polymerization in many processes, but how WRC senses Arf signaling is unknown. Here, we have reconstituted a direct interaction between Arf and WRC. This interaction is greatly enhanced by Rac1 binding to the D site of WRC. Arf1 binds to a previously unidentified, conserved surface on the Sra1 subunit of WRC, which, in turn, drives WRC activation using a mechanism distinct from that of Rac1. Mutating the Arf binding site abolishes Arf1-WRC interaction, disrupts Arf1-mediated WRC activation, and impairs lamellipodia formation and cell migration. This work uncovers a new mechanism underlying WRC activation and provides a mechanistic foundation for studying how WRC-mediated actin polymerization links Arf and Rac signaling in cells.
Structural Valve Deterioration After Self-Expanding Transcatheter or Surgical Aortic Valve Implantation in Patients at Intermediate or High Risk
O’Hair, Daniel, Yakubov, Steven J. , Oh, Jae K. , Deeb, G. Michael, Bajwa, Tanvir , Kleiman, Neal S. , Chetcuti, Stanley, Gada, Hemal, Mumtaz, Mubashir , Heiser, John, Merhi, William , Petrossian, George , Robinson, N. Bryce , Tang, Gilbert H.L. , Rovin, Joshua D. , Little, Stephen H. , Jain, Renuka , Verdoliva, Sarah , Hanson, Tim, Li, Shuzhen , Popma, Jeffrey J. , Reardon, Michael J. , Ito, Saki , Reardon, Michael J , Grubb, Kendra J , Deeb, G. Michael , Mieghem, Nicolas M. Van , Adams, David , Søndergaard, Lars , Hanson, Tim

Mayo Clinic

JAMA Cardiology | December 14, 2022 | Volume: 8 | Issue: 2 | Pages: 111

10.1001/jamacardio.2022.4627 | PMID 36515976 Get It

ImportanceThe frequency and clinical importance of structural valve deterioration (SVD) in patients undergoing self-expanding transcatheter aortic valve implantation (TAVI) or surgery is poorly understood.ObjectiveTo evaluate the 5-year incidence, clinical outcomes, and predictors of hemodynamic SVD in patients undergoing self-expanding TAVI or surgery.Design, Setting, and ParticipantsThis post hoc analysis pooled data from the CoreValve US High Risk Pivotal (n = 615) and SURTAVI (n = 1484) randomized clinical trials (RCTs); it was supplemented by the CoreValve Extreme Risk Pivotal trial (n = 485) and CoreValve Continued Access Study (n = 2178). Patients with severe aortic valve stenosis deemed to be at intermediate or increased risk of 30-day surgical mortality were included. Data were collected from December 2010 to June 2016, and data were analyzed from December 2021 to October 2022.InterventionsPatients were randomized to self-expanding TAVI or surgery in the RCTs or underwent self-expanding TAVI for clinical indications in the nonrandomized studies.Main Outcomes and MeasuresThe primary end point was the incidence of SVD through 5 years (from the RCTs). Factors associated with SVD and its association with clinical outcomes were evaluated for the pooled RCT and non-RCT population. SVD was defined as (1) an increase in mean gradient of 10 mm Hg or greater from discharge or at 30 days to last echocardiography with a final mean gradient of 20 mm Hg or greater or (2) new-onset moderate or severe intraprosthetic aortic regurgitation or an increase of 1 grade or more.ResultsOf 4762 included patients, 2605 (54.7%) were male, and the mean (SD) age was 82.1 (7.4) years. A total of 2099 RCT patients, including 1128 who received TAVI and 971 who received surgery, and 2663 non-RCT patients who received TAVI were included. The cumulative incidence of SVD treating death as a competing risk was lower in patients undergoing TAVI than surgery (TAVI, 2.20%; surgery, 4.38%; hazard ratio [HR], 0.46; 95% CI, 0.27-0.78; P = .004). This lower risk was most pronounced in patients with smaller annuli (23 mm diameter or smaller; TAVI, 1.32%; surgery, 5.84%; HR, 0.21; 95% CI, 0.06-0.73; P = .02). SVD was associated with increased 5-year all-cause mortality (HR, 2.03; 95% CI, 1.46-2.82; P < .001), cardiovascular mortality (HR, 1.86; 95% CI, 1.20-2.90; P = .006), and valve disease or worsening heart failure hospitalizations (HR, 2.17; 95% CI, 1.23-3.84; P = .008). Predictors of SVD were developed from multivariate analysis.Conclusions and RelevanceThis study found a lower rate of SVD in patients undergoing self-expanding TAVI vs surgery at 5 years. Doppler echocardiography was a valuable tool to detect SVD, which was associated with worse clinical outcomes.Trial RegistrationClinicalTrials.gov Identifiers: NCT01240902, NCT01586910, and NCT01531374
Sorrow on the Shoreline
Brandeland, Megan A. , Schick, Alexandra, White, Caroline, White, Caroline

Mayo Clinic

JAMA Cardiology | December 14, 2022 | Volume: 8 | Issue: 2 | Pages: 105

10.1001/jamacardio.2022.4609 | PMID 36515924 Get It

This essay describes 3 health care workers who unexpectedly encounter a patient in need.
Case Report of a Diabetic Foot Infection Caused by Staphylococcus pseudintermedius, a Zoonotic Pathogen of Canine Origin
Bobbitt, Kimberly L., Winder, Michelle , Kvas, Stephanie P.

Mayo Clinic

Journal of the American Podiatric Medical Association | December 14, 2022 | Volume: 112 | Issue: 6 | Pages: No page available

10.7547/21-114 | PMID 36525328 Get It

Staphylococcus pseudintermedius is an emerging zoonotic pathogen that is very similar to human Staphylococcus pathogens, particularly multidrug-resistant Staphylococcus aureus . Recent reports have indicated that S pseudintermedius is easily transmitted between pets (mainly dogs) and owners because of these similarities. Although this pathogen has been associated with diabetic foot infections, it has not yet been described in the podiatric medical literature. In this case report, we present a diabetic foot infection in a 61-year-old man that was refractory to multiple rounds of antibiotic drug therapy. Deep wound cultures eventually grew S pseudintermedius , which was the first known case of this pathogen reported in our hospital system.
Mesenchymal Stem Cell–mediated Image-guided Sodium Iodide Symporter ( NIS ) Gene Therapy Improves Survival of Glioblastoma-bearing Mice
Kitzberger, Carolin , Spellerberg, Rebekka , Han, Yang , Schmohl, Kathrin A. , Stauss, Christina , Zach, Christian , Kälin, Roland E. , Eiber, Matthias , Schilling, Franz , Glaß, Rainer , Weber, Wolfgang , Wagner, Ernst , Nelson, Peter J. , Spitzweg, Christine , Multhoff, Gabriele , Eiber, Matthias , Schilling, Franz , Glass, Rainer , Weber, Wolfgang A , Wagner, Ernst , Nelson, Peter J , Spitzweg, Christine

Mayo Clinic

Clinical Cancer Research | December 14, 2022 | Volume: 29 | Issue: 5 | Pages: 930-942

10.1158/1078-0432.ccr-22-1433 | PMID 36516189 Get It

Abstract Purpose: Mesenchymal stem cells (MSC) have emerged as cellular-based vehicles for the delivery of therapeutic genes in cancer therapy based on their inherent tumor-homing capability. As theranostic gene, the sodium iodide symporter (NIS) represents a successful target for noninvasive radionuclide-based imaging and therapy. In this study, we applied genetically engineered MSCs for tumor-targeted NIS gene transfer in experimental glioblastoma (GBM)—a tumor with an extremely poor prognosis. Experimental Design: A syngeneic, immunocompetent GL261 GBM mouse model was established by subcutaneous and orthotopic implantation. Furthermore, a subcutaneous xenograft U87 model was used. Bone marrow–derived MSCs were stably transfected with a NIS-expressing plasmid driven by the constitutively active cytomegalovirus promoter (NIS-MSC). After multiple or single intravenous injection of NIS-MSCs, tumoral iodide uptake was monitored in vivo using 123I-scintigraphy or 124I-PET. Following validation of functional NIS expression, a therapy trial with 131I was performed on the basis of the most optimal application regime as seen by 124I-PET imaging in the orthotopic approach. Results: A robust tumoral NIS-specific radionuclide accumulation was observed after NIS-MSC and radioiodide application by NIS-mediated in vivo imaging. NIS immunofluorescence staining of GBM and non-target tissues showed tumor-selective MSC homing along with NIS expression. Application of therapeutically effective 131I led to significantly delayed tumor growth and prolonged median survival after NIS-MSC treatment as compared with controls. Conclusions: A strong tumor-selective recruitment of systemically applied MSCs into GBM was found using NIS as reporter gene followed by successful therapeutic application of radioiodide demonstrating the potential use of NIS-based MSCs as therapy vehicles as a new GBM therapy approach.
Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma
Switchenko, Jeffrey M. , Bachanová, Veronika , Gerson, James N. , Gordon, Max J. , Danilov, Alexey V. , Grover, Natalie S. , Mathews, Stephanie , Burkart, Madelyn , Hill, Brian T. , Park, Steven , Fenske, Timothy S. , Martin, Peter W., Malecek, Mary‐Kate , Flowers, Christopher R. , Link, Brian K. , Kaplan, Lawrence D. , Inwards, David J. , Maddocks, Kami J. , Blum, Kristie A. , Bartlett, Nancy L. , Leonard, John P. , Cohen, Jonathon B. , Epperla, Narendranath , Switchenko, Jeffrey , Grover, Natalie S , Burkart, Madelyn , Karmali, Reem , Sawalha, Yazeed , Ghosh, Nilanjan , Park, Steven I , Bond, David A , Hamadani, Mehdi , Kahl, Brad S , Link, Brian K , Feldman, Andrew L , Hsi, Eric D , Bartlett, Nancy L , Cerhan, James R , Maurer, Matthew , Cohen, Jonathon B , Bachanova, Veronika , Epperla, Narendranath , Barta, Stefan K , Karmali, Reem , Sawalha, Yazeed , Bond, David A. , Hamadani, Mehdi , Martin, Peter, Kahl, Brad S. , Feldman, Andrew L. , Hsi, Eric D. , Cerhan, James R. , Habermann, Thomas M. , Maurer, Matthew J.

Mayo Clinic

Blood Advances | December 14, 2022 | Volume: 7 | Issue: 11 | Pages: 2287-2296

10.1182/bloodadvances.2022009225 | PMID 36516079 Get It

Abstract The prognostic relevance of diagnosis to treatment interval (DTI) in patients with newly diagnosed mantle cell lymphoma (MCL) is unknown. Hence, we sought to evaluate the impact of DTI on outcomes in MCL using 3 large datasets (1) the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource, (2) patients enrolled in the ALL Age Asthma Cohort/CALGB 50403, and (3) a multisitecohort of patients with MCL. Patients were a priori divided into 2 groups, 0 to 14 days (short DTI) and 15 to 60 days (long DTI). The patients in whom observation was deemed appropriate were excluded. One thousand ninety-seven patients newly diagnosed with MCL and available DTI were included in the study. The majority (73%) had long DTI (n=797). Patients with short DTI had worse eastern cooperative oncology group performance status (ECOG PS ≥2), higher lactate dehydrogenase, bone marrow involvement, more frequent B symptoms, higher MCL International Prognostic Index (MIPI ≥6.2), and were less likely to receive intensive induction therapy than long DTI group. The median progression-free survival (2.5 years vs 4.8 years, p<0.0001) and overall survival (7.8 years vs. 11.8 years, p<0.0001) were significantly inferior in the short DTI group than the long DTI cohort and remained significant for progression-free survival and overall survival in multivariable analysis. We show that the DTI is an important prognostic factor in patients newly diagnosed with MCL and is strongly associated with adverse clinical factors and poor outcomes. DTI should be reported in all the patients newly diagnosed with MCL who are enrolling in clinical trials and steps must be taken to ensure selection bias is avoided.